Artem Andreevich Venediktov

Mr. Artem Andreevich Venediktov

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Biomarker Insights
Verified
Journal Article
Open access
OPOlesya A Puchenkova
Olesya A Puchenkova
VSVladislav Soldatov
Vladislav Soldatov
ABAndrei E Belykh
Andrei E Belykh
OBOlgaYu Bushueva
OlgaYu Bushueva
Gennadii PiavchenkoGennadii Piavchenko
Gennadii Piavchenko
MPMikhail V Pokrovskiy
Mikhail V Pokrovskiy
Abdominal aortic aneurysm (AAA) is a potentially life-threatening disorder with a mostly asymptomatic course where the abdominal aorta is weakened and bulged. Cytokines play especially important roles (both positive and negative) among the molecular actors of AAA development. All the inflammatory cascades, extracellular matrix degradation and vascular smooth muscle cell apoptosis are driven by cytokines. Previous studies emphasize an altered expression and a changed epigenetic regulation of key cytokines in AAA tissue samples. Such cytokines as IL-6, IL-10, IL-12, IL-17, IL-33, IL-1β, TGF-β, TNF-α, IFN-γ, and CXCL10 seem to be crucial in AAA pathogenesis. Some data obtained in animal studies show a protective function of IL-10, IL-33, and canonical TGF-β signaling, as well as a dual role of IL-4, IFN-γ and CXCL10, while TNF-α, IL-1β, IL-6, IL-12/IL-23, IL-17, CCR2, CXCR2, CXCR4 and the TGF-β noncanonical pathway are believed to aggravate the disease. Altogether data highlight significance of cytokines as informative markers and predictors of AAA. Pathologic serum/plasma concentrations of IL-1β, IL-2, IL-6, TNF-α, IL-10, IL-8, IL-17, IFN-γ, and PDGF have been already found in AAA patients. Some of the changes correlate with the size of aneurysms. Moreover, the risk of AAA is associated with polymorphic variants of genes encoding cytokines and their receptors: CCR2 (rs1799864), CCR5 (Delta-32), IL6 (rs1800796 and rs1800795), IL6R (rs12133641), IL10 (rs1800896), TGFB1 (rs1800469), TGFBR1 (rs1626340), TGFBR2 (rs1036095, rs4522809, rs1078985), and TNFA (rs1800629). Finally, 5 single-nucleotide polymorphisms in gene coding latent TGF-β-binding protein ( LTBP4) and an allelic variant of TGFB3 are related to a significantly slower AAA annual growth rate.

19 April 2024 in Sechenov Medical Journal
Verified
Journal Article
Open access
PDF file
Egor KuzminEgor Kuzmin
Egor Kuzmin
ZSZ. V. Shamitko
Z. V. Shamitko
Gennadii PiavchenkoGennadii Piavchenko
Gennadii Piavchenko
AVArtem Andreevich Venediktov
Artem Andreevich Venediktov
MIM. Yu. Ivanova
M. Yu. Ivanova
SKSergey L. Kuznetsov
Sergey L. Kuznetsov
Inflammatory processes accompanied by damage to the cell bodies of neurons are combined into the group of neuroinflammation. At the molecular, cellular and tissue levels, neuroinflammation serves as a sanogenetic response to a variety of injuries, including post-traumatic conditions and neurodegeneration. However, inflammatory changes in long-lived cells such as neurons inevitably trigger a range of adverse effects. As a result, prognosis often depends on the severity of neuroinflammation. In this work, we review the spectrum of biomarkers involved in two key mechanisms of neuroinflammation: immune-mediated and mechanical injury, that have a potential clinical application: cytokines, neurospecific proteins and their proteolysis products, markers of oxidative stress, matrix metalloproteinases and endocrine parameters. Over the past decades, a significant pool of data on neuroinflammation biomarkers has been accumulated and continues to grow, but no consensus has been reached on the actual gradation of their clinical significance. Applied branches of medicine require further systematization of information on biomarkers of neuroinflammation for effective prognostic decisions.

1 June 2023 in Gels
Verified
Journal Article
Open access
PDF file
MSMurat Shagidulin
Murat Shagidulin
NONina Onishchenko
Nina Onishchenko
VSVictor I. Sevastianov
Victor I. Sevastianov
МКМиша Крашенинников
Миша Крашенинников
ALAlexey Lyundup
Alexey Lyundup
SGSergey Gautier
Sergey Gautier
Our study sought approaches for chronic liver failure (CLF) treatment and correction via cell-engineered constructs (CECs). They are built from biopolymer-based, microstructured, and collagen-containing hydrogel (BMCG). We also strove to evaluate the functional activity of BMCG in liver regeneration. Materials and Methods: Allogeneic liver cells (namely, hepatocytes; LC) together with mesenchymal multipotent stem cells of bone marrow origin (MMSC BM; BMSCs) were adhered to our BMCG to compose implanted liver CECs. Thereafter, we investigated a model of CLF in rats receiving the implanted CECs. The CLF had been provoked by long-term exposure to carbon tetrachloride. The study comprised male Wistar rats (n = 120) randomized into 3 groups: Group 1 was a control group with the saline treatment of the hepatic parenchyma (n = 40); Group 2 received BMCG only (n = 40); and Group 3 was loaded with CECs implanted into the parenchyma of their livers (n = 40). August rats (n = 30) made up a donor population for LCs and MMSC BM to develop grafts for animals from Group 3. The study length was 90 days. Results: CECs were shown to affect both biochemical test values and morphological parameters in rats with CLF. Conclusion: We found BMCG-derived CECs to be operational and active, with regenerative potential. Group 3 showed significant evidence of forced liver regeneration that tended to persist until the end of the study (day 90). The phenomenon is reflected by biochemical signs of hepatic functional recovery by day 30 after grafting (compared to Groups 1 and 2), whereas structural features of liver repair (necrosis prevention, missing formation of vacuoles, degenerating LC number decrease, and delay of hepatic fibrotic transformation). Such implantation of BMCG-derived CECs with allogeneic LCs and MMSC BM might represent a proper option to correct and treat CLF, as well as to maintain affected liver function in patients with liver grafting needed.

4 August 2022 in Polymers
Verified
Journal Article
Open access
PDF file
MSMurat Shagidulin
Murat Shagidulin
NONina Onishchenko
Nina Onishchenko
AGAnastasiia Grechina
Anastasiia Grechina
ANAlla Nikolskaya
Alla Nikolskaya
МКМиша Крашенинников
Миша Крашенинников
SGSergey Gautier
Sergey Gautier
Aim: In this study, we seek to check if recombinant spidroin rS1/9 is applicable for cell-engineering construct development. Novel technologies of cell and tissue engineering are relevant for chronic liver failure management. Liver regeneration may represent one of the possible treatment options if a cell-engineered construct (CEC) is used. Nowadays, one can see the continuous study of various matrices to create an appropriate CEC. Materials and Methods: We have adhered allogenic liver cells and multipotent mesenchymal bone marrow stem cells (MMSC BM) to a microgel with recombinant spidroin rS1/9. Then we have studied the developed implantable CEC in a rat model (n = 80) of chronic liver failure achieved by prolonged poisoning with carbon tetrachloride. Results: Our results demonstrate that the CECs change the values of biochemical tests and morphological parameters in chronic liver failure in rats. Conclusion: We consider there to be a positive effect from the microgel-based CECs with recombinant spidroin rS1/9 in the treatment of chronic liver failure.

29 November 2023 in Sechenov Medical Journal
Verified
Journal Article
Open access
PDF file
Gennadii PiavchenkoGennadii Piavchenko
Gennadii Piavchenko
AVArtem Andreevich Venediktov
Artem Andreevich Venediktov
Egor KuzminEgor Kuzmin
Egor Kuzmin
SKSergey L. Kuznetsov
Sergey L. Kuznetsov
Aim. We sought to assess the effects of exogenous Hsp70 (single subcutaneous low- and high-dose injections) on organ structure and functions in adult mice.Materials and methods. We randomized CD1 90-day-old male mice (n = 30) to three groups (10 mice per group). We injected the animals with single subcutaneous saline solution for Group 1 (control), low dose (500 μg/kg) of recombinant human Hsp70 (HspA1A) for Group 2, and high dose (5000 μg/kg) of the Hsp70 for Group 3. We examined the behavior of the mice on Day 3 after the injections (distance traveled, velocity, and bowel movement number). We lethalized the mice on Day 5 with further histological study and morphometrics of cerebral cortex, thymus, spleen, and liver. The statistics included one-factor ANOVA test with post hoc Tukey test.Results. All study groups exhibited no significant difference of behavioral parameters. Some liver sinusoids were wider in control group and Hsp70 500 μg/kg group comparing to Hsp70 5000 μg/kg group. We obtained also data for morphometrics: no difference was found for the number of neurons in ganglionic cerebral cortex, the lymphocytic cellularity difference between thymic cortex and medulla, the number of lymphocytes in white splenic pulp, and the number of hepatocyte nuclei in the liver. Red splenic pulp exhibited 1774,5 ± 24,8, 1623,0 ± 26,7, 1553,6 ± 47,0 macrophages for control, low-dose and high-dose groups, respectively (р < 0,0001). Tukey test showed a significant difference between control group and each of Hsp70 groups 500 μg/kg (р = 0,012) and 5000 μg/kg (р < 0,0001).Conclusion. Our study revealed no negative impact of subcutaneous Hsp70 administration at low and high doses on organ structure and functions in mice.

12 December 2024 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Gennadii PiavchenkoGennadii Piavchenko
Gennadii Piavchenko
Ksenia Sergeevna PokidovaKsenia Sergeevna Pokidova
Ksenia Sergeevna Pokidova
Egor KuzminEgor Kuzmin
Egor Kuzmin
AVArtem Andreevich Venediktov
Artem Andreevich Venediktov
IIIlya Izmailov
Ilya Izmailov
SKSergey L. Kuznetsov
Sergey L. Kuznetsov
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease, often linked to mutations in the FUS gene, leading to toxic protein aggregates. This study investigates the role of HSP70, a molecular chaperone, in mitigating neurodegeneration in FUS-ALS mouse models. Using quantitative immunofluorescence microscopy, we mapped cellular changes in the primary motor cortex of double transgenic FUS/HSP70 mice and compared them to single FUS-transgenic controls. Our results reveal that double transgenic mice exhibit significantly reduced neuronal damage and increased levels of mature neuronal (NeuN) and microglial (Iba1) markers, indicating a protective effect of HSP70. Intracellular HSP70 expression proved more effective than extracellular release, suggesting that targeted HSP70 delivery to neurons may offer a promising therapeutic avenue for ALS. This study underscores the potential of quantitative immunofluorescence for mapping neuroprotective pathways and highlights HSP70’s impact on mitigating FUS-related pathology in ALS.